Ghent University Academic Bibliography

Journal Article
A1
open access

Safety and immunogenicity of a carbohydrate fatty acid monosulphate ester adjuvant combined with a low-dose quadrivalent split-virion inactivated influenza vaccine : a randomised, observer-blind, active-controlled, first-in-human, phase 1 study

Valentino D'Onofrio (UGent) , Sharon Porrez (UGent) , Bart Jacobs (UGent) , Azhar Alhatemi (UGent) , Fien De Boever (UGent) , Gwenn Waerlop (UGent) , Els Michels, Francesca Vanni, Alessandro Manenti, Geert Leroux-Roels (UGent) , et al.

(2024) VACCINES. 12(9).

Add to list

Journal Article
A1
open access

Evaluation of safety, immunogenicity and cross-reactive immunity of OVX836, a nucleoprotein-based universal influenza vaccine, in older adults

Bart Jacobs, Isabel Leroux-Roels (UGent) , Jacques Bruhwyler, Nicola Groth, Gwenn Waerlop (UGent) , Yorick Janssens (UGent) , Jessika Tourneur, Fien De Boever (UGent) , Azhar Alhatemi (UGent) , Philippe Moris, et al.

(2024) VACCINES. 12(12).

Add to list

Journal Article
A1
open access

Safety and immunogenicity of the live-attenuated hRVFV-4s vaccine against Rift Valley fever in healthy adults : a dose-escalation, placebo-controlled, first-in-human, phase 1 randomised clinical trial

Isabel Leroux-Roels (UGent) , Chittappen Kandiyil Prajeeth, Amare Aregay, Niranjana Nair, Guus F Rimmelzwaan, Albert D M E Osterhaus, Simone Kardinahl, Sabrina Pelz, Stephan Bauer, Valentino D'Onofrio (UGent) , et al.

(2024) LANCET INFECTIOUS DISEASES. 24(11). p.1245-1253

Add to list

Journal Article
A1
open access

Double-blind, placebo-controlled, dose-escalating study evaluating the safety and immunogenicity of an epitope-specific chemically defined nanoparticle RSV vaccine

Isabel Leroux-Roels (UGent) , Jacques Bruhwyler, Lilli Stergiou, Mark Sumeray, Jasper Joye, Cathy Maes, Paul-Henri Lambert and Geert Leroux-Roels (UGent)

(2023) VACCINES. 11(2).

Add to list

Journal Article
A1
open access

Immune responses in healthy adults elicited by a bivalent norovirus vaccine candidate composed of GI.4 and GII.4 VLPs without adjuvant

Gwenn Waerlop (UGent) , Yorick Janssens (UGent) , Bart Jacobs (UGent) , Franziska Jarczowski, André Diessner, Geert Leroux-Roels (UGent) , Victor Klimyuk, Isabel Leroux-Roels (UGent) and Frank Thieme

(2023) FRONTIERS IN IMMUNOLOGY. 14.

Add to list

Journal Article
A1
open access

A human monoclonal antibody against HBsAg for the prevention and treatment of chronic HBV and HDV infection

Rani Burm, Freya Van Houtte (UGent) , Lieven Verhoye (UGent) , Ahmed Atef Ahmed Abouzeid Mesalam (UGent) , S Ciesek, P Roingeard, H Wedemeyer, Geert Leroux-Roels (UGent) and Philip Meuleman (UGent)

(2023) JHEP REPORTS. 5(3).

Add to list

Journal Article
A1
open access

Immunogenicity, safety, and preliminary efficacy evaluation of OVX836, a nucleoprotein-based universal influenza A vaccine candidate : a randomised, double-blind, placebo-controlled, phase 2a trial

Isabel Leroux-Roels (UGent) , Paul Willems, Gwenn Waerlop (UGent) , Yorick Janssens (UGent) , Jessika Tourneur, Fien De Boever (UGent) , Jacques Bruhwyler, Azhar Alhatemi (UGent) , Bart Jacobs (UGent) , Florence Nicolas, et al.

(2023) LANCET INFECTIOUS DISEASES. 23(12). p.1360-1369

Add to list

Journal Article
A1
open access

Human immunity and susceptibility to influenza A(H3) viruses of avian, equine, and swine origin

Elien Vandoorn, Wojciech Stadejek (UGent) , Isabel Leroux-Roels (UGent) , Geert Leroux-Roels (UGent) , Anna Parys and Kristien Van Reeth (UGent)

(2023) EMERGING INFECTIOUS DISEASES. 29(1). p.98-109

Add to list

Journal Article
A2
open access

Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults : a phase 2 randomized study

Xavier Saez-Llorens, Claudio Lanata, Elaine Aranguren, Carlos R. Celis, Rubelio Cornejo, Rodrigo DeAntonio, Lucie Ecker, Diegi Garrido, Ana I. Gil, Marina Gonzales, et al.

(2022) VACCINE: X. 11.

Add to list

Journal Article
A1
open access

Characterization of the cell-mediated immune response to Takeda’s live-attenuated tetravalent dengue vaccine in adolescents participating in a phase 2 randomized controlled trial conducted in a dengue-endemic setting

Vianney Tricou, Raphael Gottardo, Michael A. Egan, Frédéric Clement (UGent) , Geert Leroux-Roels (UGent) , Xavier Sáez-Llorens, Astrid Borkowski, Derek Wallace and Hansi J. Dean

(2022) VACCINE. 40(8). p.1143-1151

Academic Bibliography

Safety and immunogenicity of a carbohydrate fatty acid monosulphate ester adjuvant combined with a low-dose quadrivalent split-virion inactivated influenza vaccine : a randomised, observer-blind, active-controlled, first-in-human, phase 1 study

Evaluation of safety, immunogenicity and cross-reactive immunity of OVX836, a nucleoprotein-based universal influenza vaccine, in older adults

Safety and immunogenicity of the live-attenuated hRVFV-4s vaccine against Rift Valley fever in healthy adults : a dose-escalation, placebo-controlled, first-in-human, phase 1 randomised clinical trial

Double-blind, placebo-controlled, dose-escalating study evaluating the safety and immunogenicity of an epitope-specific chemically defined nanoparticle RSV vaccine

Immune responses in healthy adults elicited by a bivalent norovirus vaccine candidate composed of GI.4 and GII.4 VLPs without adjuvant

A human monoclonal antibody against HBsAg for the prevention and treatment of chronic HBV and HDV infection

Immunogenicity, safety, and preliminary efficacy evaluation of OVX836, a nucleoprotein-based universal influenza A vaccine candidate : a randomised, double-blind, placebo-controlled, phase 2a trial

Human immunity and susceptibility to influenza A(H3) viruses of avian, equine, and swine origin

Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults : a phase 2 randomized study

Characterization of the cell-mediated immune response to Takeda’s live-attenuated tetravalent dengue vaccine in adolescents participating in a phase 2 randomized controlled trial conducted in a dengue-endemic setting

Contents

Support

Contact